Pouya Mahdavi Sharif

Dr. Pouya Mahdavi Sharif

Pediatric Cell and Gene Therapy Research Center, Tehran University of Medical Sciences, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Cytokine
Verified
Journal Article
Closed access
Pouya Mahdavi SharifPouya Mahdavi Sharif
Pouya Mahdavi Sharif
PJParnian Jabbari
Parnian Jabbari
SRSepideh Razi
Sepideh Razi
MKMahsa Keshavarz-Fathi
Mahsa Keshavarz-Fathi
NRNima Rezaei
Nima Rezaei

2 March 2023 in Survey of Ophthalmology
Verified
Journal Article
Closed access
MSMohammad Soleimani
Mohammad Soleimani
Pouya Mahdavi SharifPouya Mahdavi Sharif
Pouya Mahdavi Sharif
KCKasra Cheraqpour
Kasra Cheraqpour
RKRaghuram Koganti
Raghuram Koganti
AMAhmad Masoumi
Ahmad Masoumi
ADAli Djalilian
Ali Djalilian

5 January 2023 in BMC Public Health
Verified
Journal Article
Open access
PDF file
Pouya Mahdavi SharifPouya Mahdavi Sharif
Pouya Mahdavi Sharif
SPSara Najafi Pazooki
Sara Najafi Pazooki
ZGZahra Ghodsi
Zahra Ghodsi
ANAhmad Nouri
Ahmad Nouri
HGHamed Abbasizade Ghoroghchi
Hamed Abbasizade Ghoroghchi
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar
Background: Road traffic injuries (RTI) are one of the most prominent causes of morbidity and mortality, especially among children and young adults. Motorcycle crashes constitute a significant part of RTIs. Policymakers believe that safety helmets are the single most important protection against motorcycle-related injuries. However, motorcyclists are not wearing helmets at desirable rates. This study systematically investigated factors that are positively associated with helmet usage among two-wheeled motorcycle riders. Methods: We performed a systematic search on PubMed, Scopus, Web of Science, Embase, and Cochrane library with relevant keywords. No language, date of publication, or methodological restrictions were applied. All the articles that had evaluated the factors associated with helmet-wearing behavior and were published before December 31, 2021, were included in our study and underwent data extraction. We assessed the quality of the included articles using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies. Results: A total of 50 articles were included. Most evidence suggests that helmet usage is more common among drivers (compared to passengers), women, middle-aged adults, those with higher educations, married individuals, license holders, and helmet owners. Moreover, the helmet usage rate is higher on highways and central city roads and during mornings and weekdays. Travelers of longer distances, more frequent users, and riders of motorcycles with larger engines use safety helmets more commonly. Non-helmet-using drivers seem to have acceptable awareness of mandatory helmet laws and knowledge about their protective role against head injuries. Importantly, complaint about helmet discomfort is somehow common among helmet-using drivers. Conclusions: To enhance helmet usage, policymakers should emphasize the vulnerability of passengers and children to RTIs, and that fatal crashes occur on low-capacity roads and during cruising at low speeds. Monitoring by police should expand to late hours of the day, weekends, and lower capacity and less-trafficked roads. Aiming to enhance the acceptance of other law-abiding behaviors (e.g., wearing seat belts, riding within the speed limits, etc.), especially among youth and young adults, will enhance the prevalence of helmet-wearing behavior among motorcycle riders. Interventions should put their focus on improving the attitudes of riders regarding safety helmets, as there is acceptable knowledge of their benefits.

5 January 2022 in Polish Journal of Radiology
Verified
Journal Article
Open access
PDF file
Pouya Mahdavi SharifPouya Mahdavi Sharif
Pouya Mahdavi Sharif
MNMehran Nematizadeh
Mehran Nematizadeh
MSMahdia Saghazadeh
Mahdia Saghazadeh
ASAmene Saghazadeh
Amene Saghazadeh
NRNima Rezaei
Nima Rezaei
Introduction: Computed tomography (CT) scan is a commonly used tool for the diagnosis of the novel coronavirus disease 2019 (COVID-19), similarly to reverse transcription-polymerase chain reaction (RT-PCR). Because of the limitations of RT-PCR, there is growing interest in the usability of the CT scan. The present systematic review and meta-analysis aims to summarize the available data on the CT scan features of COVID-19.Material and methods: We conducted a systematic search in electronic databases to find eligible studies published between 1 December 2019 and 4 April 2020, which investigated the computed tomographic features of patients with COVID-19. All preprint and peer-reviewed articles were included. No language limitation was applied. For proportional data, pooled prevalence was calculated using a Freeman-Tukey double arcsine transformation, with a 95% confidence interval (CI).Results: Eighty-six studies were eligible to be included in the meta-analysis. For 7956 patients, the most common CT findings were bilateral pattern of involvement (78%; 95% CI: 0.73-0.82; p < 0.001), involvement of more than 1 lobe (75%; 95% CI: 0.68-0.82; p < 0.001), ground-glass opacities (GGO) (73%; 95% CI: 0.67-0.78; p < 0.001), and periphe­ral distribution of signs (69%; 95% CI: 0.61-0.76; p < 0.001). Only 5% of patients had a normal CT scan (95% CI: 0.03-0.07; p < 0.001). The proportion of paediatric patients (age < 18 years) with unremarkable CT findings was higher (40%; 95% CI: 0.27-0.55; p < 0.001). Subgroup analysis showed that patients with the severe or critical type of COVID-19 were more likely to have pleural effusion (RR 7.77; 95% CI: 3.97-15.18; p < 0.001) and consolidation (RR 3.13; 95% CI: 1.57-6.23; p < 0.001). CT results in patients with COVID-19 were comparable with those of people having pneumonia from other causes, except for the lower incidence of consolidation (RR 0.81; 95% CI: 0.71-0.91; p < 0.001) and higher risk of showing GGO (RR 1.45; 95% CI: 1.13-1.86; p < 0.001). The mortality rate was slightly higher in patients with bilateral involvement (RR 3.19; 95% CI: 1.07-9.49; p = 0.04).Conclusions: Our study results show that COVID-19 shares some features with other viral types of pneumonia, despite some differences. They commonly present as GGO along with vascular thickening, air bronchogram and consolidations. Normal CT images, lymphadenopathies, and pleural effusions are not common. Consolidations and pleural effusions correlate with more severe disease. CT features are different between COVID-19 and non-COVID-19 pneumonia. Also, they differ by age, disease severity, and outcomes within COVID-19 patients.

9 April 2022 in Accident Analysis & Prevention
Verified
Journal Article
Closed access
EMEsmaeil Mohammadi
Esmaeil Mohammadi
SASina Azadnajafabad
Sina Azadnajafabad
MKMohammad Keykhaei
Mohammad Keykhaei
ASAli Shakiba
Ali Shakiba
SMSepideh Ebrahimi Meimand
Sepideh Ebrahimi Meimand
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar

9 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RMRashin Mohseni
Rashin Mohseni
Pouya Mahdavi SharifPouya Mahdavi Sharif
Pouya Mahdavi Sharif
MBMaryam Behfar
Maryam Behfar
SSSahar Shojaei
Sahar Shojaei
ASAlireza Shoae-Hassani
Alireza Shoae-Hassani
Amir Ali HamidiehAmir Ali Hamidieh
Amir Ali Hamidieh
Despite low incidence, neuroblastoma, an immunologically cold tumor, is the most common extracranial solid neoplasm in pediatrics. In relapsed/refractory cases, the benefits of autologous hematopoietic stem cell transplantation (auto-HSCT) and other therapies are limited. Natural killer (NK) cells apply cytotoxicity against tumor cells independently of antigen-presenting cells and the adaptive immune system. The primary endpoint of this trial was to assess the safety of the injection of allogenic, ex vivo-expanded and primed NK cells in relapsed/refractory neuroblastoma patients after auto-HSCT. The secondary endpoint included the efficacy of this intervention in controlling tumors. NK cells were isolated and primed ex vivo (by adding interleukin [IL]-2, IL-15, and IL-21) in a GMP-compliant CliniMACS system and administered to four patients with relapsed/refractory MYCN-positive neuroblastoma. NK cell injections (1 and 5 × 107 cells/kg in the first and second injections, respectively) were safe, and no acute or sub-acute adverse events were observed. During the follow-up period, one complete response (CR) and one partial response (PR) were observed, while two cases exhibited progressive disease (PD). In follow-up evaluations, two died due to disease progression, including the case with a PR. The patient with CR had regular growth at the 31-month follow-up, and another patient with PD is still alive and receiving chemotherapies 20 months after therapy. This therapy is an appealing and feasible approach for managing refractory neuroblastomas post-HSCT. Further studies are needed to explore its efficacy with higher doses and more frequent administrations for high-risk neuroblastomas and other immunologically cold tumors. Trial registration number: irct.behdasht.gov.ir (Iranian Registry of Clinical Trials, No. IRCT20201202049568N1).